JP5483731B2 - 保存可能な生虫卵懸濁液の製造 - Google Patents
保存可能な生虫卵懸濁液の製造 Download PDFInfo
- Publication number
- JP5483731B2 JP5483731B2 JP2010501415A JP2010501415A JP5483731B2 JP 5483731 B2 JP5483731 B2 JP 5483731B2 JP 2010501415 A JP2010501415 A JP 2010501415A JP 2010501415 A JP2010501415 A JP 2010501415A JP 5483731 B2 JP5483731 B2 JP 5483731B2
- Authority
- JP
- Japan
- Prior art keywords
- suspension
- acid
- eggs
- oral administration
- preservatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000725 suspension Substances 0.000 title claims abstract description 48
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 5
- 235000013601 eggs Nutrition 0.000 claims abstract description 52
- 239000003755 preservative agent Substances 0.000 claims abstract description 37
- 244000000013 helminth Species 0.000 claims abstract description 18
- 230000002335 preservative effect Effects 0.000 claims abstract description 18
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract description 16
- 108010034145 Helminth Proteins Proteins 0.000 claims abstract description 13
- 230000003071 parasitic effect Effects 0.000 claims abstract description 9
- 241000960389 Trichuris suis Species 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 31
- 244000005700 microbiome Species 0.000 claims description 30
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 14
- 238000010306 acid treatment Methods 0.000 claims description 11
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 11
- 235000010199 sorbic acid Nutrition 0.000 claims description 11
- 239000004334 sorbic acid Substances 0.000 claims description 11
- 229940075582 sorbic acid Drugs 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- 239000005711 Benzoic acid Substances 0.000 claims description 9
- 235000010233 benzoic acid Nutrition 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 230000001332 colony forming effect Effects 0.000 claims description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 4
- 230000037406 food intake Effects 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- -1 p-hydroxybenzoic acid ester Chemical class 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 abstract description 3
- 244000052637 human pathogen Species 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 15
- 230000001418 larval effect Effects 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000035899 viability Effects 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 241000714201 Feline calicivirus Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000006968 Helminthiasis Diseases 0.000 description 3
- 241000714177 Murine leukemia virus Species 0.000 description 3
- 208000030852 Parasitic disease Diseases 0.000 description 3
- 241000702619 Porcine parvovirus Species 0.000 description 3
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 241001489151 Trichuris Species 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- CMMUKUYEPRGBFB-UHFFFAOYSA-L dichromic acid Chemical compound O[Cr](=O)(=O)O[Cr](O)(=O)=O CMMUKUYEPRGBFB-UHFFFAOYSA-L 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000003253 viricidal effect Effects 0.000 description 2
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000244188 Ascaris suum Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 244000040311 Eucharis candida Species 0.000 description 1
- 239000012028 Fenton's reagent Substances 0.000 description 1
- 206010054272 Helicobacter gastritis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001439624 Trichina Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/124—Disinfecting agents, e.g. antimicrobials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07006838A EP1977643A1 (de) | 2007-04-02 | 2007-04-02 | Herstellung einer viablen, lagerfähigen Wurmeiersuspension |
| EP07006838.2 | 2007-04-02 | ||
| PCT/EP2008/002542 WO2008119534A1 (de) | 2007-04-02 | 2008-03-31 | Herstellung einer viablen, lagerfähigen wurmeiersuspension |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010523506A JP2010523506A (ja) | 2010-07-15 |
| JP2010523506A5 JP2010523506A5 (cg-RX-API-DMAC7.html) | 2011-03-17 |
| JP5483731B2 true JP5483731B2 (ja) | 2014-05-07 |
Family
ID=38330156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501415A Expired - Fee Related JP5483731B2 (ja) | 2007-04-02 | 2008-03-31 | 保存可能な生虫卵懸濁液の製造 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9017700B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1977643A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5483731B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101646340B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE520304T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008234080B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2682525C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1111898T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2129216T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2368536T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20110715T1 (cg-RX-API-DMAC7.html) |
| ME (1) | ME01257B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2129216T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2129216E (cg-RX-API-DMAC7.html) |
| RS (1) | RS51938B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2483740C2 (cg-RX-API-DMAC7.html) |
| SI (1) | SI2129216T1 (cg-RX-API-DMAC7.html) |
| UA (1) | UA96480C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008119534A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201402909D0 (en) * | 2014-02-19 | 2014-04-02 | Univ Southampton | Treating infection |
| US9603875B1 (en) * | 2016-01-07 | 2017-03-28 | NeuOva, LLC | Method of making a consumable product with purified embryonated Trichuris suis ova |
| FR3085687B1 (fr) * | 2018-09-07 | 2021-05-14 | Nolivade | Composition et procede de conservation |
| CN109370908A (zh) * | 2018-11-16 | 2019-02-22 | 中农威特生物科技股份有限公司 | 一种鸡球虫卵囊的培养和保存液及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2059417C1 (ru) * | 1992-10-01 | 1996-05-10 | Данилевич Василий Николаевич | Способ стерилизации питательных сред |
| WO1999033479A1 (en) * | 1997-12-31 | 1999-07-08 | University Of Iowa Research Foundation | Use of parasitic biological agents for prevention and control of autoimmune diseases |
| DE10163115A1 (de) * | 2001-12-24 | 2003-07-03 | Alpha Biocare Gmbh | Reinigung und Desinfektion von Eiern von Nematoden und Plathelminthen |
| US20050118655A1 (en) * | 2003-11-17 | 2005-06-02 | University Of Iowa Research Foundation | Use of parasitic biological agents for diseases prevention and control |
| DK1968618T3 (en) * | 2005-12-30 | 2017-08-28 | Parasite Tech As | COMPOSITION OF COMPREHENSIVE PARASITES AND PROCEDURES FOR THE ISOLATION AND STORAGE OF PARASITES |
-
2007
- 2007-04-02 EP EP07006838A patent/EP1977643A1/de not_active Withdrawn
-
2008
- 2008-03-31 ES ES08734901T patent/ES2368536T3/es active Active
- 2008-03-31 JP JP2010501415A patent/JP5483731B2/ja not_active Expired - Fee Related
- 2008-03-31 CA CA2682525A patent/CA2682525C/en not_active Expired - Fee Related
- 2008-03-31 EP EP08734901A patent/EP2129216B1/de active Active
- 2008-03-31 PL PL08734901T patent/PL2129216T3/pl unknown
- 2008-03-31 HR HR20110715T patent/HRP20110715T1/hr unknown
- 2008-03-31 PT PT08734901T patent/PT2129216E/pt unknown
- 2008-03-31 UA UAA200910740A patent/UA96480C2/ru unknown
- 2008-03-31 RU RU2009140308/15A patent/RU2483740C2/ru not_active IP Right Cessation
- 2008-03-31 AU AU2008234080A patent/AU2008234080B2/en not_active Ceased
- 2008-03-31 WO PCT/EP2008/002542 patent/WO2008119534A1/de not_active Ceased
- 2008-03-31 DK DK08734901.5T patent/DK2129216T3/da active
- 2008-03-31 RS RS20110416A patent/RS51938B/sr unknown
- 2008-03-31 ME MEP-2011-165A patent/ME01257B/me unknown
- 2008-03-31 AT AT08734901T patent/ATE520304T1/de active
- 2008-03-31 US US12/594,074 patent/US9017700B2/en not_active Expired - Fee Related
- 2008-03-31 CN CN2008800104022A patent/CN101646340B/zh not_active Expired - Fee Related
- 2008-03-31 SI SI200830386T patent/SI2129216T1/sl unknown
-
2011
- 2011-09-30 CY CY20111100945T patent/CY1111898T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE520304T1 (de) | 2011-09-15 |
| EP2129216A1 (de) | 2009-12-09 |
| ME01257B (me) | 2013-06-20 |
| RS51938B (sr) | 2012-02-29 |
| ES2368536T3 (es) | 2011-11-18 |
| EP1977643A1 (de) | 2008-10-08 |
| DK2129216T3 (da) | 2011-10-24 |
| HRP20110715T1 (hr) | 2011-11-30 |
| PT2129216E (pt) | 2011-09-27 |
| AU2008234080A1 (en) | 2008-10-09 |
| JP2010523506A (ja) | 2010-07-15 |
| CN101646340A (zh) | 2010-02-10 |
| UA96480C2 (ru) | 2011-11-10 |
| US20110008390A1 (en) | 2011-01-13 |
| CY1111898T1 (el) | 2015-11-04 |
| CN101646340B (zh) | 2013-01-02 |
| SI2129216T1 (sl) | 2011-11-30 |
| US9017700B2 (en) | 2015-04-28 |
| PL2129216T3 (pl) | 2011-11-30 |
| CA2682525A1 (en) | 2008-10-09 |
| HK1133551A1 (en) | 2010-04-01 |
| RU2009140308A (ru) | 2011-05-10 |
| EP2129216B1 (de) | 2011-08-17 |
| RU2483740C2 (ru) | 2013-06-10 |
| CA2682525C (en) | 2015-11-17 |
| WO2008119534A1 (de) | 2008-10-09 |
| AU2008234080B2 (en) | 2013-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI114852B (fi) | Antimikrobisena aineena käytettävä hapotettu nitraatti | |
| BR112019011015A2 (pt) | uso de uma composição, formulação e seu uso, lubrificante vaginal prebiótico e uso de uma cápsula vaginal simbiótica | |
| JP5483731B2 (ja) | 保存可能な生虫卵懸濁液の製造 | |
| CN105263489B (zh) | 抗微生物组合物及其制造方法 | |
| CN114129547B (zh) | 香芹酚在提高耐甲氧西林金黄色葡萄球菌对β-内酰胺类抗生素敏感性方面的应用 | |
| CN111700910A (zh) | 一种避免人感染动物病菌的清洗消毒液 | |
| TWI826874B (zh) | 用於預防或控制球蟲病之不含抗生素的組合物 | |
| CN102311932A (zh) | 改善口腔内细菌群的唾液乳酸杆菌及其保健组合物 | |
| CN115350197B (zh) | 泽泻醇A-24-醋酸酯在提高MRSA对β-内酰胺类抗生素敏感性方面的应用 | |
| CN110946857A (zh) | 一种没食子儿茶素及其在制备肠道病原菌药物和饲料添加剂 | |
| JPWO2019098241A1 (ja) | 乳房炎用医薬組成物、および治療方法 | |
| CN116747221A (zh) | 一种抗菌组合物及其制备方法和应用 | |
| KR101242535B1 (ko) | 콕시듐 치료 및 예방을 위한 조성물의 제조방법 | |
| CN114869871A (zh) | 紫檀茋在抗水产养殖动物嗜水气单胞菌感染中的应用 | |
| HK1133551B (en) | Production of a viable, storable worm egg suspension | |
| Timonin et al. | Bacteriostatic activity of citrinin in vitro | |
| RU2545986C1 (ru) | Препарат траметин для лечения желудочно-кишечных болезней телят и способ его применения | |
| KR20230155155A (ko) | 마크로라이드 계열 항생제를 유효성분으로 포함하는 개과 동물의 호흡기 질환의 예방 또는 치료용 조성물 | |
| CN118986949A (zh) | 莽草酸作为万古霉素治疗耐甲氧西林金黄色葡萄球菌感染性心内膜炎的体内增效剂中的应用 | |
| KR20240146920A (ko) | 콕시듐 백신을 위한 집충 방법과 소독 방법 | |
| CN117838676A (zh) | 黄腐酚在制备抗水产养殖动物嗜水气单胞菌感染药物中的应用 | |
| CZ290100B6 (cs) | Farmaceutický prostředek pro prevenci a léčení mikrobiálních průjmů u zvířat | |
| CN112603916A (zh) | 月桂酸在制备沙门氏菌ⅲ型分泌系统抑制剂中的应用 | |
| Berglund et al. | The dynamics of intraperitoneal growth and elimination of Escherichia coli and Bacteroides fragilis in porcine faecal peritonitis treated with fosfomycin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110128 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130122 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130418 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130425 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130624 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140212 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140217 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5483731 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |